Phathom Pharmaceuticals

Yahoo Finance • 2 months ago

Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder’s Ownership Following Administrative Change to 13D Filing

FLORHAM PARK, N.J., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), today clarified that a Schedule 13D filing by Frazier Life Sciences, which is expected to be filed later today, August 20, will include a... Full story

Yahoo Finance • 2 months ago

Phathom projects $165M–$175M 2025 revenue as GI sales focus accelerates VOQUEZNA growth

Earnings Call Insights: Phathom Pharmaceuticals (PHAT) Q2 2025 MANAGEMENT VIEW * Steven L. Basta, CEO, indicated that the quarter marked "a meaningful inflection point for Phathom" as the company builds a growth-oriented and profitable... Full story

Yahoo Finance • 2 months ago

Phathom Pharmaceuticals (NASDAQ:PHAT) Surpasses Q2 Estimates with Strong VOQUEZNA Growth, Shares Jump 6% in Premarket

PHATHOM PHARMACEUTICALS (NASDAQ:PHAT) BEATS Q2 REVENUE AND EPS ESTIMATES, SHARES RISE IN PREMARKET Phathom Pharmaceuticals (NASDAQ:PHAT [https://www.chartmill.com/stock/quote/PHAT]) reported second-quarter 2025 financial results that surp... Full story

Yahoo Finance • 3 months ago

Phathom Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide Business Update on Thursday, August 7, 2025

Management to host conference call on Thursday, August 7, 2025, at 8:00 am EDT FLORHAM PARK, N.J., July 28, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and com... Full story

Yahoo Finance • 4 months ago

Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announce... Full story

Yahoo Finance • 4 months ago

Phathom says FDA confirmed Voqueza exclusivity through May 2032

[FDA headquarters in Washington DC.] JHVEPhoto/iStock Editorial via Getty Images * Phathom Pharmaceuticals (NASDAQ:PHAT [https://seekingalpha.com/symbol/PHAT]) said that the U.S. FDA has updated its "Orange Book" to reflect that Voquezn... Full story

Yahoo Finance • 4 months ago

Phathom Pharmaceuticals Announces FDA Correction to Orange Book Listing, Confirming 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets Through May 3, 2032

FLORHAM PARK, N.J., June 16, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announce... Full story

Yahoo Finance • 4 months ago

Phathom surges 125% after FDA grants petition on Voquezna exclusivity

[Going Up] Richard Drury Phathom Pharmaceuticals has shot up ~125% in Friday trading after the U.S. FDA granted their Citizen Petition regarding the expiration date of new chemical entity exclusivity for their drug Voquezna (vonoprazan).... Full story

Yahoo Finance • 4 months ago

Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets through May 3, 2032

FLORHAM PARK, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) today announced that the U.S. Food and Drug Administration (FDA) has approved Phathom’s Citizen Petition filed on December 11, 2024 and co... Full story

Yahoo Finance • 6 months ago

Phathom Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide Business Update on Thursday, May 1, 2025

• Management to host conference call on Thursday, May 1, 2025, at 8:00 am EDT FLORHAM PARK, N.J., April 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and com... Full story

Yahoo Finance • 6 months ago

Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors

FLORHAM PARK, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced th... Full story

Yahoo Finance • 6 months ago

Phathom Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference

FLORHAM PARK, N.J., April 03, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced tod... Full story

Yahoo Finance • 6 months ago

Phathom Pharmaceuticals Announces Leadership Succession

FLORHAM PARK, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announc... Full story

Yahoo Finance • 7 months ago

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

VOQUEZNA® (vonoprazan) generated $55.3 million in 2024 net revenues in its first full year of launch, driven by strong demand, including $29.7 million in Q4, an 81% increase from Q3Over 300,000 filled prescriptions for VOQUEZNA products, l... Full story

Yahoo Finance • 8 months ago

Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 6, 2025

Management to host conference call on Thursday, March 6, 2025, at 8:30 am ET FLORHAM PARK, N.J., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and comme... Full story

Yahoo Finance • 8 months ago

Phathom Pharmaceuticals to Present at the Guggenheim Securities SMID Cap Biotech Conference

FLORHAM PARK, N.J., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced toda... Full story

Yahoo Finance • 2 years ago

Phathom Pharmaceuticals Announces Expansion of Existing Loan and Security Agreement with Hercules Capital

Phathom Pharmaceuticals Amendment provides more favorable terms including a 14-month extension of the interest-only period and maturity date until December 2027 Up to an additional $100 million in non-dilutive capital available subject t... Full story

Yahoo Finance • 2 years ago

Phathom Pharmaceuticals Announces Commercial Availability of VOQUEZNA® (vonoprazan) Tablets, a Powerful First-In-Class PCAB for the Treatment of Erosive GERD and Relief of Associated Heartburn

VOQUEZNA, the first and only FDA-approved potassium-competitive acid blocker (PCAB), is now available through major retail pharmacies and BlinkRx, an end-to-end digital fulfillment channel VOQUEZNA tablets in 30-count bottles are now comme... Full story

Yahoo Finance • 2 years ago

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT)

NEW YORK, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky announces that it has commenced an investigation of Phantom Pharmaceuticals, Inc. (NASDAQ: PHAT) concerning possible breaches of fiduciary duty. To obtain additional informatio... Full story

Yahoo Finance • 2 years ago

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) and Encourages Investors to Contact the Firm

PHILADELPHIA, Nov. 11, 2023 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) (“Phathom”) on behalf of the company’s investors. Since August 2023, shares of Phathom’s com... Full story